Press "Enter" to skip to content

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process – GlobeNewswire

admin 0

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process  GlobeNewswire

MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage …

“colorectal cancer” – Google News

(Visited 25 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *